Table 4.

Mean QALYs and costs and cost-effectiveness acceptability analysis, UK £’s, 2018–2019 prices

Follow-up	Control (61/132, 46%)				RDSI (41/131, 31%)
	Mean	SE	95% CI		Mean	SE	95% CI
QALYS
Baseline to 4-week follow-up	0.044	0.002	0.040	0.047	0.052	0.003	0.046	0.057
4–12 weeks follow-up	0.088	0.004	0.080	0.095	0.104	0.005	0.093	0.114
Baseline to 12 weeks follow-up	0.133	0.005	0.122	0.143	0.154	0.007	0.140	0.169
Costs
Baseline to 4-week follow-up	£461	£134	£195	£726	£784	£522	£<1	£1820
4–12 weeks follow-up	£659	£176	£310	£1008	£1450	£812	£<1	£3060
Baseline to 12 weeks follow-up	£1120	£242	£639	£1600	£2234	£1320	£<1	£4851
Bootstrapped estimates	Net QALY or Cost of RDSI vs control		95% percentiles		Probability RDSI is cost-effective
					WTPT= £0 per QALY gained	WTPT= £15 000 per QALY gained	WTPT= £30 000 per QALY gained
Primary analysis (complete cost and QALY data, n=102)
Net QALYs	0.019		0.001; 0.037		0.06	0.14	0.23
Net cost	£1401		−£544; £3347
Sensitivity analysis (available cost and QALY data, indicator for incomplete data, n=147)
Net QALYs	0.015		0.001; 0.030		0.06	0.13	0.21
Net cost	£1142		-£824; £3108

QALY, Quality Adjusted Life Years; RDSI, respiratory distress symptom intervention; WTPT, willingness-to-pay threshold.